Heart failure & cardiomyopathiesSecondary analysis
Diuretic Dosing and Outcomes with Torsemide and Furosemide Following Hospitalization for Heart Failure: The TRANSFORM-HF Trial
- Post-hoc analysis of the TRANSFORM-HF randomised trial
Authors' conclusion
Following hospitalization for heart failure, higher loop diuretic dosing was independently associated with worse clinical and patient-reported outcomes.
Study context
- Population
- Patients discharged after hospitalization for HF in the TRANSFORM-HF trial (torsemide vs furosemide)
- Participants
- 2,379 patients
- Comparison
- Discharge loop diuretic dose groups, by torsemide or furosemide
- Primary endpoint
- Primary and secondary clinical outcomes by discharge diuretic dose: clinical events and change in KCCQ-CSS
- Follow-up
- 12 months
Primary result
As reported in the abstract
All-cause mortality
Each group vs group 1Adjusted hazard ratio (95% CI)
Group 2furosemide
1.21(0.91–1.59)
Group 3furosemide
1.40(1.04–1.88)
Group 2torsemide
1.74(1.32–2.30)
Group 3torsemide
1.58(1.14–2.19)
Further findings
All-cause hospitalization; composite of all-cause mortality and hospitalization · 12 months
- Higher doses of furosemide and torsemide associated with increased risk, no heterogeneity by loop diuretic type
- P for interaction > 0.2
Change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) from baseline · 12 months
- Similar across dose groups for both drugs
Original publication
Diuretic Dosing and Outcomes with Torsemide and Furosemide Following Hospitalization for Heart Failure: The TRANSFORM-HF Trial. Eur J Heart Fail. Published 4 October 2024. doi:10.1002/ejhf.3458
Summarised from the published abstract; every number is checked against it